Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Share on StockTwits

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,626 shares of the biopharmaceutical company’s stock after purchasing an additional 778 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Gilead Sciences were worth $800,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Gilead Sciences by 0.7% in the second quarter. Vanguard Group Inc. now owns 102,062,449 shares of the biopharmaceutical company’s stock valued at $6,895,339,000 after acquiring an additional 715,569 shares in the last quarter. Invesco Ltd. raised its holdings in Gilead Sciences by 17.5% in the second quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock valued at $1,552,213,000 after acquiring an additional 3,418,193 shares in the last quarter. Northern Trust Corp raised its holdings in Gilead Sciences by 2.1% in the second quarter. Northern Trust Corp now owns 17,187,741 shares of the biopharmaceutical company’s stock valued at $1,161,204,000 after acquiring an additional 347,443 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Gilead Sciences by 56.9% in the second quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock valued at $860,731,000 after acquiring an additional 4,620,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 0.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 12,109,533 shares of the biopharmaceutical company’s stock valued at $818,120,000 after acquiring an additional 90,251 shares in the last quarter. 80.03% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences stock traded down $0.25 during mid-day trading on Tuesday, hitting $64.39. The company had a trading volume of 285,407 shares, compared to its average volume of 6,286,513. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11. The stock has a market cap of $82.72 billion, a price-to-earnings ratio of 10.47, a PEG ratio of 3.47 and a beta of 1.09. The business has a fifty day moving average of $64.10 and a 200 day moving average of $65.28. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $72.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.01. The business had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period last year, the firm posted $1.84 earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

Several analysts recently weighed in on the stock. Raymond James reduced their target price on shares of Gilead Sciences from $85.00 to $81.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Citigroup set a $78.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a research note on Monday, July 29th. Bank of America began coverage on shares of Gilead Sciences in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $70.00 price target on the stock. Finally, Robert W. Baird set a $76.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $78.87.

In other news, Director Olsen Per Wold sold 4,908 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total transaction of $313,670.28. Following the transaction, the director now directly owns 102,762 shares in the company, valued at $6,567,519.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 5,677 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the transaction, the executive vice president now owns 21,521 shares in the company, valued at $1,362,494.51. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,288 shares of company stock worth $1,108,682. Insiders own 0.20% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Strangles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NexTier Oilfield Solutions  Trading 7% Higher
NexTier Oilfield Solutions Trading 7% Higher
Hertz Global  Stock Price Up 5.7%
Hertz Global Stock Price Up 5.7%
Gol Linhas Aereas Inteligentes  Trading 6.6% Higher
Gol Linhas Aereas Inteligentes Trading 6.6% Higher
Transportadora de Gas del Sur  Trading 6.3% Higher
Transportadora de Gas del Sur Trading 6.3% Higher
Teloscoin  Trading Up 9% Over Last 7 Days
Teloscoin Trading Up 9% Over Last 7 Days
INLOCK Price Up 26.3% Over Last Week
INLOCK Price Up 26.3% Over Last Week


© 2006-2019 Ticker Report